Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines ...

A surge in clinical trials investigating potential idiopathic pulmonary fibrosis therapies offers patients new hope, ...

The new data from PureTech come after the company reported successful results from the phase 2b Elevate study in December ...

The latest results from the phase 3 FIBRONEER-IPF trial showed consistent benefit of nerandomilast in patients with ...

Even a 2% decline in lung function predicted poor outcomes for patients with idiopathic pulmonary fibrosis (IPF) in a new ...

Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines ...

Rein Therapeutics has initiated the randomised RENEW Phase II trial of its Caveolin-1-related peptide, LTI-03, targeting ...

LTI-03 is formulated as a dry powder inhalation therapy that's designed to help ease fibrosis and symptoms of idiopathic ...

Most patients with IPF have inspiratory dry crackles ("velcro-type") on auscultation of the chest. Clubbing of the fingers occurs in about half the cases. More advanced cases may present with signs of ...

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced positive top-line Phase II study results for its novel ...

Roughly one in five (21 percent) of idiopathic pulmonary fibrosis (IPF) deaths might be related to occupational exposures, according to research published in the March 6 issue of the U.S. Centers ...

The Phase II study is evaluating Cumberland's ifetroban product candidate in patients with idiopathic pulmonary fibrosis (IPF), the most common form of progressive fibrosing interstitial lung disease.